Anteris Technologies delivering on its goals despite pandemic
Anteris Technologies Ltd's (ASX:AVR) Wayne Paterson tells Proactive's Andrew Scott the recent name change from Admedus is to reflect the single focus they have on structural heart and leveraging its assets into much more higher-value propositions. Paterson updates on its main trials which are underway and says he's extremely thrilled with the results to date from its first-in-human study. Paterson's expecting the company will end the year achieving all milestones set for 2020.
ShareCafe's Hidden Gems Webinar – Anteris (AVR)
Latest video outlining Anteris direction to build the World's Most Durable Heart Valve
StockPal Interview with Wayne Paterson
Anteris Technologies (ASX:AVR) – Wayne Paterson
Bioshares - Admedus Name Change
Admedus has changed its name to Anteris Technologies
Company Name Change
Change of company name from Admedus to Anteris Technologies
Admedus 2020 AGM
Admedus 2020 AGM Video
CEO Wayne Paterson is interviewed by Proactive Investors
CEO Wayne Paterson is interviewed by proactive investors to provide an update on Admedus in light of COVID-19
First patient implanted with DurAVR™
Admedus implants first patient with their 3D single piece aortic valve
Investor Q&A with Dr. Paul Sorajja & our CEO
Dr. Paul Sorajja shares his view on Admedus' TAVR
Admedus is proud to announce the successful implantation of its ADAPT® treated single piece 3D aortic valve.
Admedus Limited announces the first implantation of its ADAPT® treated 3D single piece aortic valve in a patient with aortic stenosis.
Credit Suisse Equity Research – US Medical Supplies & Devices
Week of Pre-Releases and Meetings Point to Solid Fundamentals and Healthy Innovation See the report here
First-In-Human SAVR Trial Begins Q1 2020
ANNOUNCEMENT First-In-Human SAVR Trial Begins Q1 2020. Admedus Limited announces approval for first-in-human surgical aortic valve replacement (SAVR) trial of its proprietary ADAPT® single-piece 3D aortic valve at the Leuven University Hospitals.